FindTrial
Sign In

IN10018

DRUG10 trials

Sponsors

InxMed (Shanghai) Co., Ltd., InventisBio Co., Ltd, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jemincare

Conditions

Cervical AdenocarcinomaGastric CancerGastric-type Endocervical AdenocarcinomaMetastatic MelanomaNSCLCNSCLC (Advanced Non-small Cell Lung Cancer)Ovarian Cancer RecurrentPancreatic Cancer

Phase 1

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma
CompletedNCT04109456
InxMed (Shanghai) Co., Ltd.Metastatic Melanoma
Start: 2020-03-16End: 2024-12-20Updated: 2026-01-15
IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma
CompletedNCT05327231
InxMed (Shanghai) Co., Ltd.Gastric Cancer
Start: 2020-07-09End: 2022-03-31Updated: 2022-11-16
Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors
Active, not recruitingNCT05379946
InventisBio Co., LtdSolid Tumor
Start: 2022-10-12End: 2025-12-31Target: 92Updated: 2025-04-08
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
RecruitingNCT05827796
InxMed (Shanghai) Co., Ltd.Pancreatic Cancer
Start: 2022-12-08End: 2026-03-31Target: 70Updated: 2025-04-30
IN10018 Combination Therapy in Previously-treated Solid Tumors
WithdrawnNCT05982522
InxMed (Shanghai) Co., Ltd.Solid Tumor
Start: 2025-08-13End: 2026-12-31Updated: 2026-03-27
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
RecruitingNCT05994131
InxMed (Shanghai) Co., Ltd.NSCLC
Start: 2023-07-13End: 2026-07-31Target: 110Updated: 2025-04-30
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
RecruitingNCT06030258
InxMed (Shanghai) Co., Ltd.Small Cell Lung Cancer Extensive Stage
Start: 2023-10-30End: 2025-12-24Target: 120Updated: 2025-04-30
A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation
RecruitingNCT06946927
JemincareNSCLC (Advanced Non-small Cell Lung Cancer)
Start: 2025-06-06End: 2027-12-31Target: 72Updated: 2025-07-01

Phase 2

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
RecruitingNCT06014528
InxMed (Shanghai) Co., Ltd.Ovarian Cancer Recurrent
Start: 2022-09-06End: 2026-12-24Target: 168Updated: 2025-04-30
IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial
RecruitingNCT06654011
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCervical Adenocarcinoma, Gastric-type Endocervical Adenocarcinoma
Start: 2025-02-17End: 2026-11-01Target: 25Updated: 2026-01-13

Related Papers

Safety and efficacy of ifebemtinib (IN10018) combined with garsorasib (D-1553) in KRAS G12C mutant solid tumors from a phase Ib/II study: Results from single-arm of non-small-cell lung cancer (NSCLC) and randomized part of colorectal cancer (CRC).
Journal of Clinical Oncology2025-05-28
Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in non-small-cell lung cancer (NSCLC) with KRAS G12C mutation: Results from a phase Ib/II study.
Journal of Clinical Oncology2024-06-017 citations